ZZPZH(SH:600436) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-04-08 23:04Transaction Overview - Recently, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. signed a technology transfer contract with Shandong Kangzhonghong Pharmaceutical Technology Development Co., Ltd. for the transfer of rights related to the traditional Chinese medicine new drug "Wenfei Dingchuan Granules" for a total fee of RMB 13.58 million [2][5] - The contract does not require approval from the board of directors or shareholders and does not constitute a related party transaction or a major asset restructuring [2][3] Counterparty Information - Shandong Kangzhonghong Pharmaceutical Technology Development Co., Ltd. is a limited liability company established on September 23, 2002, with a registered capital of RMB 30 million [3] - The company is not a dishonest executor and has no relationship with Zhangzhou Pien Tze Huang Pharmaceutical [3] Transaction Target Information - The transaction involves the intellectual property rights of "Wenfei Dingchuan Granules," including clinical trial approval notices, production rights, development rights, usage rights, and transfer rights [4] - The granules are intended for treating chronic obstructive pulmonary disease and have no similar products approved for the same indications in the domestic market [4] Contract Details - The technology transfer includes all relevant data, materials, and rights associated with "Wenfei Dingchuan Granules," with Kangzhonghong providing technical guidance during the development phase [6] - The total transfer fee is RMB 13.58 million, to be paid in installments [6] - All developed results and subsequent development rights will belong to Zhangzhou Pien Tze Huang Pharmaceutical after the contract is signed [6] Impact on the Company - The execution of the contract aligns with the company's strategic development goals and enhances its existing research pipeline, improving competitiveness and profitability [6]